Skip to main content
Clinical Trials/EUCTR2013-005118-36-ES
EUCTR2013-005118-36-ES
Active, not recruiting
Phase 1

A clinical study of Patients with symptomatic neurogenic orthostatic HypOtENsion to assess sustaIned effects of droXidopa therapy - PHOENIX

Chelsea Therapeutics, Incorporated0 sites450 target enrollmentMay 22, 2014

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Chelsea Therapeutics, Incorporated
Enrollment
450
Status
Active, not recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 22, 2014
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Chelsea Therapeutics, Incorporated

Eligibility Criteria

Inclusion Criteria

  • 1\. 18 years or older and ambulatory (defined as able to walk at least 10 meters)
  • 2\. Clinical diagnosis of symptomatic orthostatic hypotension associated with Primary Autonomic Failure (PD, MSA, and PAF) or Dopamine Beta Hydroxylase Deficiency
  • 3\. At the Baseline visit (Visit 2\), patients must demonstrate:
  • a. a score of at least 4 or greater on the Orthostatic Hypotension Symptom Assessment (OHSA) Item \#1
  • b. a fall of at least 20 mmHg in their SBP, within 3 minutes of standing
  • 4\. Provide written informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 27

Exclusion Criteria

  • 1\. Score of 23 or lower on the mini\-mental state examination (MMSE)
  • 2\. Concomitant use of vasoconstricting agents for the purpose of increasing blood pressure;
  • a. Patients taking vasoconstricting agents such as ephedrine, dihydroergotamine, or midodrine must stop taking these drugs at least 2 days or 5 half\-lives (whichever is longer) prior to their baseline visit (Visit 2\) and throughout the duration of the study
  • 3\. Known or suspected alcohol or substance abuse within the past 12 months
  • 4\. Women who are pregnant or breastfeeding
  • 5\. Women of childbearing potential (WOCP) who are not using at least one method of contraception with their partner
  • 6\. Sustained supine hypertension greater than or equal to 180 mmHg systolic or 110 mmHg diastolic, or have these measurements at their Baseline Visit (Visit 2\). Sustained is defined as measurements persistently greater at 2 separate measurements at least 10 minutes apart with the subject supine and at rest for at least 5 minutes
  • 7\. Untreated closed angle glaucoma
  • 8\. Diagnosis of hypertension that requires treatment with antihypertensive medications (short\-acting antihypertensives to treat nocturnal supine hypertension are allowed in this study)
  • 9\. Any significant uncontrolled cardiac arrhythmia

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A study to look at the long-term effects of droxidopa treatment in patients who experience low blood pressure when changing their posture
EUCTR2013-005118-36-ITChelsea Therapeutics, Incorporated450
Completed
Not Applicable
Grouping of nerve signs in people with neck and arm paiHealth Condition 1: G55- Nerve root and plexus compressionsin diseases classified elsewhere
CTRI/2019/02/017594Manipal Academy of Higher Education246
Completed
Not Applicable
Patients' experiences with neuraltherapy during an inpatient stay at the Clinic of Complementary and Integrative Medicine- a qualitative study with semistructured interviewsdiseases for which neuraltherapy is indicated
DRKS00004567niversität Duisburg-EssenLehrstuhl und Klinik für Naturheilkund und Integrative Medizin, Knappschafts-Krankenhaus,Kliniken Essen-Mitte22
Recruiting
Not Applicable
Register study on neuroprognostics in patients with neurological / neurosurgical diseases in intensive care unitI63I61I67I60S06D33D43C71G00G01G02G03A87A32B05G09A17B00B01B02B45G04G05A81A83A84A85A86A39G60G61G92G70G73G35G36G62G63G64G71G72M60M63M33E88G31G40G93E72G41G12G20G21G23G10F02F00F01F03F04F05F10F13T65Cerebral infarctionIntracerebral haemorrhageOther cerebrovascular diseasesSubarachnoid haemorrhageIntracranial injuryBenign neoplasm of brain and other parts of central nervous systemNeoplasm of uncertain or unknown behaviour of brain and central nervous systemMalignant neoplasm of brainBacterial meningitis, not elsewhere classifiedMeningitis in bacterial diseases classified elsewhereMeningitis in other infectious and parasitic diseases classified elsewhereMeningitis due to other and unspecified causesViral meningitisListeriosisMeaslesSequelae of inflammatory diseases of central nervous systemTuberculosis of nervous systemHerpesviral [herpes simplex] infectionsVaricella [chickenpox]Zoster [herpes zoster]CryptococcosisEncephalitis, myelitis and encephalomyelitisEncephalitis, myelitis and encephalomyelitis in diseases classified elsewhereAtypical virus infections of central nervous systemMosquito-borne viral encephalitisTick-borne viral encephalitisOther viral encephalitis, not elsewhere classifiedUnspecified viral encephalitisMeningococcal infectionHereditary and idiopathic neuropathyInflammatory polyneuropathyToxic encephalopathyMyasthenia gravis and other myoneural disordersDisorders of myoneural junction and muscle in diseases classified elsewhereMultiple sclerosisOther acute disseminated demyelinationOther polyneuropathiesPolyneuropathy in diseases classified elsewhereOther disorders of peripheral nervous systemPrimary disorders of musclesOther myopathiesMyositisDisorders of muscle in diseases classified elsewhereDermatopolymyositisOther metabolic disordersOther degenerative diseases of nervous system, not elsewhere classifiedEpilepsyOther disorders of brainOther disorders of amino-acid metabolismStatus epilepticusSpinal muscular atrophy and related syndromesParkinson diseaseSecondary parkinsonismOther degenerative diseases of basal gangliaHuntington diseaseDementia in other diseases classified elsewhereDementia in Alzheimer diseaseVascular dementiaUnspecified dementiaOrganic amnesic syndrome, not induced by alcohol and other psychoactive substancesDelirium, not induced by alcohol and other psychoactive substancesMental and behavioural disorders due to use of alcoholMental and behavioural disorders due to use of sedatives or hypnoticsToxic effect of other and unspecified substances
DRKS00025259Klinik für Neurologie mit experimenteller Neurologie der Charité Universitätsmedizin Berlin, Campus Charité Mitte1,700
Active, not recruiting
Not Applicable
Systemic symptoms caused by pollen allergy
JPRN-jRCT1030210077Watanabe Yoshihiro400